ResearcherInstitut Gustave RoussyActive in the last 2 years

Axel Le Cesne

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8006-8659; OpenAlex author ID A5090103193. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 3

Papers, trials and grants by year

2023: 2 papers · 2024: none · 2025: 1 paper

Papers 3

Selpercatinib for RET-positive advanced pancreatic cancer detected by liquid biopsy: a case-based insight. Last author DOI 10.1080/14622416.2025.2602419 ↗
KRAS G12C mutation: from black sheep to key player in pancreatic cancer treatment Last author DOI 10.2217/fon-2023-0067 ↗
NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned? Co-author DOI 10.2217/fon-2023-0088 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Tarek Assi · 3 shared papers, 2023–2025 · strength 0.78
Rebecca Ibrahim · 2 shared papers, 2023 · strength 0.48
- Paper KRAS G12C mutation: from black sheep to key player in pancreatic cancer treatment DOI 10.2217/fon-2023-0067 ↗
- Paper NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned? DOI 10.2217/fon-2023-0088 ↗
Rita Khoury · 2 shared papers, 2023 · strength 0.48
- Paper KRAS G12C mutation: from black sheep to key player in pancreatic cancer treatment DOI 10.2217/fon-2023-0067 ↗
- Paper NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned? DOI 10.2217/fon-2023-0088 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.